Phase 1-2 Study of Onapristone in Patients With Progesterone Receptor Expressing Cancers
Sponsor: Arno Therapeutics
Listed as NCT02052128, this PHASE1/PHASE2 trial focuses on Progesterone Receptor Positive Tumor: Max 1 Line of Prior Chemotherapy, no Prior Hormone Therapy and remains ongoing. Sponsored by Arno Therapeutics, it has been updated 7 times since 2014, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE1/PHASE2
Status: Unknown Status → Unknown · Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status PHASE1_PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Unknown Status PHASE1_PHASE2
-
Jul 2017 — Jun 2018 [monthly]
Unknown Status PHASE1_PHASE2
Status: Recruiting → Unknown Status
▶ Show 2 earlier versions
-
Feb 2017 — Jul 2017 [monthly]
Recruiting PHASE1_PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE1_PHASE2
First recorded
Jan 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Arno Therapeutics
For direct contact, visit the study record on ClinicalTrials.gov .